Slide 1: Leaders in Developing Allogeneic γδ1 CAR-T Cell Therapies to Fight Autoimmune Diseases and Cancer
Leaders in Developing Allogeneic γδ1 CAR-T Cell Therapies to Fight Autoimmune Diseases and Cancer γδ= Gamma delta; CAR= Chimeric antigen receptor
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc. (Adicet) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are not limited to,
Slide 3: ADI-001 Phase 1 Clinical Data Suggest a Transformational Approach to Treating Autoimmune Disorders
WHAT WE WANTED TO SEE WHAT WE OBSERVED 'Off-the-shelf' therapy with no need for leukapheresis 'Off-the-shelf' availability and no need for leukapheresis Favorable safety profile appropriate for outpatient administration Well tolerated safety profile: No ≥Gr2 CRS, no ICANS Appropriate for outpatient
Slide 4: Developing Broad Pipeline of Allogeneic γδ1 T Cell Therapies for Autoimmune Diseases and Cancer
Program Target Indication Research IND-Enabling Clinical Status AUTOIMMMUNE DISEASES ADI-001 CD20 LN & SLE Enrolling Fast Track Designations SSc Enrolling Fast Track Designation IIM/ SPS Open for enrollment AAV Open for enrollment RA Open for enrollment ONCOLOGY ADI-212 PSMA (gene-edited w/ armor) +
Slide 5: 2026 Potential Milestones
2026 Potential Milestones 2026 1H 2H ADI-001 AUTOIMMUNE ADI-212 ONCOLOGY mCRPC Cash and cash equivalents: ~$125.0M (6/30/25) Subject to site activation, patient enrollment, data readouts and regulatory feedback AAV= Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis; Cy/Flu= Cyclo
Slide 6: Adicet Bio Leadership Team
Adicet Bio Leadership Team Julie Maltzman, M.D. Chief Medical Officer Chen Schor President and CEO Nick Harvey Chief Financial Officer Don Healey, Ph.D. Chief Technology Officer Blake Aftab, Ph.D. Chief Scientific Officer Amy Locke Head of Human Resources
Slide 7: ADI-001 A Transformational Approach to Treating Autoimmune Disorders
ADI-001 A Transformational Approach to Treating Autoimmune Disorders
Slide 8: ADI-001 Data Summary
ADI-001 Data Summary Rapid and sustained reductions in SLEDAI-2K and PGA across all patients Improved kidney function in all five LN patients, including three complete renal responses (and DORIS remissions) and two partial renal responses, with all responses ongoing Well tolerated: No ≥Gr2 CRS, no I
Slide 9: Major Unmet Needs in LN/SLE Remain
Major Unmet Needs in LN/SLE Remain Need for one-time therapy with favorable safety profile that can deliver treatment-free remissions Treatment-free remissions are rare Flares are common despite chronic therapy, reflecting ongoing disease activity Increased early mortality due to organ damage, cardi
Slide 10: ADI-001 Phase 1 Autoimmune Study Design
ADI-001 Phase 1 Autoimmune Study Design Screening Lymphodepletion Treatment DLT Period (28 days) Follow Up LTFU Study Consent Day -28 Enrollment Single ADI-001 Infusion Day 0 Response/Safety Assessments Day 28 Response/Safety Assessments Months 3-6-9-12-18-24 Cyclophosphamide / Fludarabine Lymphodep
Slide 11: ADI-001 Phase 1 Autoimmune Study Endpoints
ADI-001 Phase 1 Autoimmune Study Endpoints Primary Endpoints Secondary & Exploratory Endpoints BVAS= Birmingham Vasculitis Activity Score; CRISS= American College of Rheumatology Composite Response Index in Systemic Sclerosis; ; CR= Complete response; CDASI= Cutaneous Dermatomyositis Disease Area an
Slide 12: Patient Baseline Characteristics
LN-1 LN-2 LN-3 LN-4 LN-5 SLE-1 SLE-2 Disease LN (Class III) LN (Class III) LN (Class III/V) LN (Class IV) LN (Class III/V) Non-Renal SLE Non-Renal SLE Dose 1E8 1E8 1E8 3E8 3E8 1E8 3E8 Age / Sex 48 / F 37 / M 32 / F 32 / F 22 / F 46 / M 37 / F Disease duration (SLE/LN; y) 4/3 22/8 6/4 10/3 2/2 2/-- 1
Slide 13: Well-Tolerated Safety Profile: Appropriate for Dosing in Outpatient Setting
Well-Tolerated Safety Profile: Appropriate for Dosing in Outpatient Setting 1E8 3E8 All dose levels # of Patients 4 3 7 SAEs -- -- -- CRS 1 (Grade 1) 1 (Grade 1) 2 (28%) ICANS 0 0 0 Infections 1 (Grade 1) 0 1 (14%) Both cases of CRS were Grade 1 (fever) Infection was Grade 1 (respiratory tract infec
Slide 14: ADI-001 Tolerability Profile Compares Favorably With Autologous αβ CAR-T Therapies
ADI-001 Tolerability Profile Compares Favorably With Autologous αβ CAR-T Therapies in Autoimmune Patients ADI-001 BMS-9863531 Rapcabtagene-autoleucel (Rap-cel)2 Obecabtagene autoleucel (Obe-cel)3 Resecabtagene autoleucel (Rese-cel)4 # of Patients 7 SLE/LN 11 SLE/LN 21 SLE/LN 6 LN 8 SLE/LN CRS (any G
Slide 15: All Five LN Patients Achieved Renal Responses, Including Three Complete Responses & DORIS Remissions
UPCR eGFR Renal response^ DORIS Remission Subj# Follow-Up (Months) Baseline Last Follow Up Baseline Last Follow Up LN-1 9 2.05 0.05 87 > 90 CRR at M1 DORIS at M6 LN-2 8 1.64 0.67 89 79 PRR at M8 LN-3 7 4.78 1.05 89 60 PRR at M7 LN-4 6 2.56 0.33 > 90 > 90 CRR at M5 DORIS at M5 LN-5 2 2.78 0.16 > 90 >
Slide 16: Significant Decline in SLEDAI-2K Across All Patients
LN-1 (1E8) LN-2 (1E8) LN-3 (1E8) LN-4 (3E8) LN-5 (3E8) SLE-1 (1E8) SLE-2 (3E8) Significant Decline in SLEDAI-2K Across All Patients Highlights ADI-001 Durable Effect On Broad Range of Lupus Symptoms Patient in DORIS remission * * * * Unavailable Anti-dsDNA and/or Complement samples were assumed pres
Slide 17: Rapid and Sustained Reductions in PGA Across All Patients
Rapid and Sustained Reductions in PGA Across All Patients Further Highlight ADI-001's Impact On Overall Disease Activity PGA (Range 0-3) DORIS remission threshold LN-1 LN-2 LN-3 LN-4 LN-5 SLE-1 SLE-2 Mean Months Cut-off date: August 31, 2025; PGA= Physician Global Assessment
Slide 18: All Patients Discontinued Immunosuppressants and Discontinued or Tapered Steroids
All patients discontinued immunosuppressants Four/seven patients discontinued corticosteroids Remaining three/seven patients tapered to physiological levels All Patients Discontinued Immunosuppressants and Discontinued or Tapered Steroids to Physiological Levels Prednisone equivalent dose (mg) physi
Slide 19: Deep and Broad B Cell Depletion Reconstitution Driven by Naïve, Non-Class Switched B Cells
Deep and Broad B Cell Depletion Reconstitution Driven by Naïve, Non-Class Switched B Cells Depletion of Clonally Dominant and Potentially Pathogenic Clones Emergence and Diversification of New BCR Repertoire Hallmarks of Immune Reset ADI-001 demonstrated evidence of immune reset: BCR= B-cell recepto
Slide 20: Deep and Broad B Cell Depletion Following ADI-001 Treatment
Deep and Broad B Cell Depletion Following ADI-001 Treatment In all patients, B cells were undetectable post-treatment with ADI-001 Circles = 1E8 dose; squares = 3E8 dose LN-1 LN-2 LN-3 LN-4 LN-5 SLE-1 SLE-2 Cut-off date: August 31, 2025; Data cut includes 7 patients with a follow-up ranging from 2-9
Slide 21: Reconstitution Driven by Naïve, Non-Class Switched B Cells
Reconstitution Driven by Naïve, Non-Class Switched B Cells Naïve (CD19+CD20+IgD+CD27-), Transitional (CD19+CD20+IgD+CD27-CD24+CD38+), Pre-class switched memory (CD19+CD20+IgD+CD27+), Memory B cells (CD19+CD20+IgD-CD27+), Plasmablasts (CD19+CD20+/-IgD-CD27highCD38highCD138-); Cut-off date: August 31,
Slide 22: Dominant BCR Clones Were Depleted Post Treatment with ADI-001
Dominant BCR Clones Were Depleted Post Treatment with ADI-001 Depletion of dominant, potentially pathogenic B cell clones present at baseline Dominant Clones Minor Clones Relative Clone Frequency Relative Clonal Frequency= B cell receptor (BCR) read count normalized to total population of BCR’s dete
Slide 23: Immune Reset of Clonally Dominant and Potentially Pathogenic Clones
Immune Reset of Clonally Dominant and Potentially Pathogenic Clones with Emergence of New B Cell Repertoire Post Treatment= 3 Months (LN-3 and LN-4) or 6 Months (LN-1); Tracking of dominant BCR clonotypes pre- and post-treatment. Node sizes are proportional to clone read count at each timepoint. Dom
Slide 24: Sustained Reductions in SLEDAI Across Industry-Sponsored Trials with Autologous CD19 CAR-T Therapies
Sustained Reductions Demonstrated in SLEDAI Across Industry-Sponsored Trials with Autologous CD19 αβ CAR-T Therapies BMS-9863531 (7 SLE/LN patients) Rap-cel2 (21 patients: 12 LN & 9 SLE) Obe-cel3 (6 LN patients) Rese-cel4 (7 SLE/LN patients) Schett et al. ACR 2024 Morand et al. EULAR 2025 Autolus R&
Slide 25: Resolution of Proteinuria Occurs More Slowly and Is Persistent in Some Patients
Resolution of Proteinuria Occurs More Slowly and Is Persistent in Some Patients Rap-cel1 (21 patients: 12 LN & 9 SLE) Morand et al. EULAR 2025 These data are derived from different trials at different points in time, with differences in trial design, including endpoints, and patient populations. As
Slide 26: Pivotal Study Design in LN/SLE With CD19 Autologous CAR-T Cell Therapies
Pivotal Study Design in LN/SLE With CD19 Autologous CAR-T Cell Therapies Obe-cel1,2 BMS-9863533,4 Rap-cel5 Indication LN (post B-cell targeting agent & calcineurin inhibitor where available) SLE & LN LN #’ SLE/LN patient data disclosed 6 (LN) 7 (LN and SLE) 12 (LN) and 9 (SLE) # of patients 35 90 15
Slide 27: ADI-001 Phase 1 Clinical Data Suggest a Transformational Approach to Treating Autoimmune Disorders
WHAT WE OBSERVED WHAT IT MEANS new ADI-001 Phase 1 Clinical Data Suggest a Transformational Approach to Treating Autoimmune Disorders Off-the-shelf with no delay in treatment due to scheduling leukapheresis and the time required for manufacturing Potential for outpatient administration; Off-the-shel
Slide 28: Momentum in Site Initiation For ADI-001 Autoimmune Program
Momentum in Site Initiation For ADI-001 Autoimmune Program Sites Initiated
Slide 29: Expanding ADI-001 Autoimmune Development Across Six Indications
Expanding ADI-001 Autoimmune Development Across Six Indications SPS AAV IIM Systemic Sclerosis SLE US Prevalence (thousand patients) ~40% with LN6 ADI-001 has the potential to change clinical practice across multiple autoimmune indications Helmick CG et al. Arthritis & Rheumatism (2008) Bairkdar M e
Slide 30: 2026 Potential Milestones
2026 Potential Milestones 2026 1H 2H ADI-001 AUTOIMMUNE ADI-212 ONCOLOGY mCRPC Cash and cash equivalents: ~$125.0M (6/30/25) Subject to site activation, patient enrollment, data readouts and regulatory feedback AAV= Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis; Cy/Flu= Cyclo
Slide 31: Leaders in Developing Allogeneic γδ1 CAR-T Cell Therapies to Fight Autoimmune Diseases and Cancer
Leaders in Developing Allogeneic γδ1 CAR-T Cell Therapies to Fight Autoimmune Diseases and Cancer γδ= Gamma delta; CAR= Chimeric antigen receptor